

**PATENT**  
Atty. Docket No.: RBN-001DV  
(9199/2)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Keene *et al.*

SERIAL NUMBER: Not yet assigned GROUP NUMBER: Not yet assigned

FILING DATE: Herewith EXAMINER: Not yet assigned

TITLE: Methods for Isolating and Characterizing Endogenous mRNA-Protein (mRNP) Complexes

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**PRELIMINARY AMENDMENT**

Sir:

This application is a divisional of U.S. Serial No. 09/750,401, filed December 28, 2000.

**AMENDMENT**

**In the Specification**

Please replace Table 2 on pages 30-31 with the following. A marked-up version of the amended table is attached at the end of this Amendment.

TABLE 2

Gene	#'UTR Consensus Sequence
CD44	AUUUUCUAUCCUUU <u>UUUAUUUAUGUCAUUUUUA</u> [SEQ ID NO: 1] <u>AAAAAAACCAAA</u> <u>UUUGAUUGGCUCUAAACA</u> [SEQ ID NO: 2]
IGF-2	UAAAGAA <u>AUUAUUGGCUAAAACAU</u> [SEQ ID NO: 3] <u>CUAAAA</u> <u>AUUAUUGGCUAAAAAA</u> [SEQ ID NO: 4]
HOX 2.5	UCACUCUU <u>AUUAUUUAU</u> [SEQ ID NO: 5] <u>AAA</u> <u>UUUAUUA</u> AGUUA [SEQ ID NO: 6] <u>AUCAGG</u> <u>UUCAUUUUGGUUGU</u> [SEQ ID NO: 7]
Inhibitor J6	AU <u>UUUAUCUGUUA</u> [SEQ ID NO: 8] <u>UUUUGUUUUUCUCCCUUUU</u> <u>UAGUUUUUCAAA</u> [SEQ ID NO: 9]
GADD45	UAUUUUUUUCUUUUUUU <u>UUUUGGUUUUAU</u> [SEQ ID NO: 10] <u>UUAAAUCUCAGAAGU</u> <u>UUUAUUA</u> AAAUCUU [SEQ ID NO: 11] <u>UUCUGUUAAAUAUU</u> <u>UUUAUUA</u> ACUGCUUUCUUUUU [SEQ ID NO: 12]
Nexin 1	AUUUUUAUAGUAGUU <u>UUUAUGUUUUUAUGGAAAA</u> [SEQ ID NO: 13] <u>AUUUGCCU</u> <u>UUUAUUCUUUUU</u> [SEQ ID NO: 14]
Egr-1	UAUUUUGUGGU <u>UUUAUUUA</u> CUUUGUACUU [SEQ ID NO: 15]
Zif268	<u>UUUUGUUUUCCUU</u> [SEQ ID NO: 16] <u>UUU</u> <u>UUUAUUUCUGUAUUUUU</u> [SEQ ID NO: 17]
Neuronal-Cadherin	<u>UUUUUUUAAAUUUU</u> <u>UUUAUUUCUUUUU</u> [SEQ ID NO: 18] <u>UUUUUUAUUUUC</u> <u>UGUAUUUUU</u> [SEQ ID NO: 19] <u>UUUUUAAUUU</u> <u>UUUAUUUUUUU</u> [SEQ ID NO: 20]
Integrin alpha 5	AAUGG <u>UUUAUUA</u> UUUAUGAU [SEQ ID NO: 21] <u>UUG</u> <u>UUUAUUA</u> CUUCAAU [SEQ ID NO: 22]
SEF2	UUCAAGCGC <u>UUGANUU</u> [SEQ ID NO: 23]
Cf2r	UGCAUCGAUCCG <u>UUGAUUUACUACU</u> [SEQ ID NO: 24]
Integrin Beta	UAUAUUU <u>UUAAUUUUUUAUUUUU</u> [SEQ ID NO: 25] <u>UUAUUUACCUUUUUUUUUUC</u> <u>UUUAUUCUGGU</u> [SEQ ID NO: 26]
CTCF	UUAUGAAUGU <u>UAAUUUUGU</u> [SEQ ID NO: 27] <u>UC</u> <u>UUAAUUUUUCUCUUUUUUUU</u> [SEQ ID NO: 28] <u>UUUUUUUUUCCU</u> <u>UUUAUUGUAAAUGGUUCUUU</u> [SEQ ID NO: 29]
TGF beta 2	UUAAUGAUCAUUCAGAUJGUA <u>UAAUUUUGUUUCCUUU</u> [SEQ ID NO: 30] <u>UUCAAUUUU</u> <u>UUUAUUA</u> ACUAUCUU [SEQ ID NO: 31] <u>UUUUUC-</u> <u>UUUAUUGGUUUUUU</u> [SEQ ID NO: 32]
MTP	UGUCUJUGUCUGAGCA <u>UUUAUUUCAAA</u> [SEQ ID NO: 33] <u>UUCUCGUCUUG</u> <u>UUUAUUUACAA</u> [SEQ ID NO: 34] <u>UAUAUAUAUAG</u> <u>UUUAUGUUUUGGAUGUUUGGU</u> [SEQ ID NO: 35]
Cyclin D2	AUGUCUJUGUCUU <u>UGUGUUUUAGGAU</u> [SEQ ID NO: 36] <u>(AU/GA)</u> <u>UUUAUUU</u> (UA/AG) [SEQ ID NO: 37]
	<u>In Vitro Consensus Sequence</u>